ECP
MXCT icon

Epacria Capital Partners’s MaxCyte MXCT Stock Holding History

Epacria Capital Partners’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,133
Closed -$96.3K – 32
2025
Q4 		$96.3K Hold
62,133
– – 0.08% 33
2025
Q3 		$98.2K Hold
62,133
– – 0.08% 34
2025
Q2 		$135K Buy
62,133
+39,796
+178% +$96.4K 0.11% 34
2025
Q1 		$61.3K Buy
+22,337
New +$88.1K 0.05% 40

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

Epacria Capital Partners's MXCT Position: Q1 2026 in Review

Epacria Capital Partners sold out of MaxCyte (MXCT) in Q1 2026, closing a stake of 62,133 shares — an estimated $96.3K sold.

Epacria Capital Partners first reported a position in MXCT in Q1 2025 and held it in 4 quarters. The position peaked at $135K in Q2 2025. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Epacria Capital Partners reported no remaining MaxCyte position as of Q1 2026 after selling out during the quarter.
  • Epacria Capital Partners sold 62,133 MaxCyte shares in Q1 2026, an estimated $96.3K.
  • Epacria Capital Partners first reported a position in MaxCyte in Q1 2025 and held it in 4 quarters.
  • Epacria Capital Partners's MaxCyte position peaked at $135K in Q2 2025.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Epacria Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.